Skip to main content

Macular Edema Secondary to Inflammation

2
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Kodiak Sciences
Kodiak SciencesCA - Palo Alto
2 programs
2
KSI-101Phase 31 trial
KSI-101Phase 31 trial
Active Trials
NCT06990399Recruiting150Est. Jul 2027
NCT06996080Recruiting150Est. Jul 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
Kodiak SciencesKSI-101
Kodiak SciencesKSI-101

Clinical Trials (2)

Total enrollment: 300 patients across 2 trials

NCT06990399Kodiak SciencesKSI-101

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Start: Jul 2025Est. completion: Jul 2027150 patients
Phase 3Recruiting
NCT06996080Kodiak SciencesKSI-101

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

Start: Jul 2025Est. completion: Jul 2027150 patients
Phase 3Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 300 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.